Latest News and Press Releases

NEWTON, Mass., Oct. 28, 2019 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for...

NEWTON, Mass., Aug. 27, 2019 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for...

NEWTON, Mass., Aug. 13, 2019 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for...

NEWTON, Mass., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for...

NEWTON, Mass., July 25, 2019 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for...

Restructuring expected to extend cash runway through end of 2020 Acer plans to discuss EDSIVO™ CRL with FDA and will continue to advance additional pipeline products NEWTON, Mass., July 05, 2019 ...

NEWTON, Mass., June 25, 2019 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for...

Pilot study using claims database suggests that a minority of U.S. vEDS patients (34%) are being treated with antihypertensive medications Data show no significant difference in clinical event rates...

NEWTON, Mass., May 23, 2019 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious...

NEWTON, Mass., May 14, 2019 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious...